World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
78
Citations
27663
World Ranking
17886
National Ranking
224

Overview

Ahmad Awada is affiliated with the Université Libre de Bruxelles in Belgium. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with significant contributions in Oncology, Pulmonary and Respiratory Medicine, and Molecular Biology as key subfields.

The main topics addressed in their research include:

  • Advanced Breast Cancer Therapies
  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Lung Cancer Research Studies
  • Cancer Treatment and Pharmacology
  • HER2/EGFR in Cancer Research
  • Brain Metastases and Treatment

Among the frequent publication venues for Awada's work are:

  • Cancer Research
  • Annals of Oncology
  • Journal of Clinical Oncology
  • ESMO Open
  • Clinical Cancer Research

Co-authors with multiple collaborations include:

  • Nuria Kotecki
  • Evandro de Azambuja
  • Martine Piccart
  • Philippe Aftimos
  • Marianne Paesmans

Recent papers featuring Ahmad Awada encompass:

  • Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial (2020, UNC Libraries)
  • Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial (2020, The Lancet Oncology) [awada is not author]
  • A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer (2020, Clinical Cancer Research) [awada is not author]
  • A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours (2020, British Journal of Cancer) [awada is not author]
  • Humanized Mice as a Valuable Pre-Clinical Model for Cancer Immunotherapy Research (2021, Frontiers in Oncology) [awada is not author]

Ahmad Awada's research shows a focus on clinical trials and cancer treatment methodologies, particularly related to breast cancer therapies and brain metastases. The collaborations and publication venues indicate an active engagement with leading oncology research communities.

Best Publications

  • Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.

    Jan B. Vermorken;Eva Remenar;Carla Van Herpen;Thierry Gorlia

  • Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

    Dirk Strumberg;Heike Richly;Ralf A. Hilger;Norbert Schleucher

  • Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.

    Sylvia Adams;Peter Schmid;Hope H.S. Rugo;Eric Winer

  • Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

    José Baselga;Seock Ah Im;Hiroji Iwata;Javier Cortés

  • Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer

    Harold J. Burstein;Yan Sun;Luc Y. Dirix;Zefei Jiang

  • Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors

    Dirk Strumberg;Jeffrey W. Clark;Ahmad Awada;Malcolm J. Moore

  • Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

    Peter A. Kaufman;Ahmad Awada;Chris Twelves;Louise Yelle

  • MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer.

    Stephen Johnston;Miguel Martin;Angelo Di Leo;Seock Ah Im

  • Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer

    Tiffany T.A. Traina;Tiffany T.A. Traina;Kathy Miller;Denise Yardley;Janice Eakle

  • Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

    A Awada;A Hendlisz;T Gil;S Bartholomeus

  • Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers

    Christian Widakowich;Christian Widakowich;Gilberto de Castro;Evandro de Azambuja;Evandro de Azambuja;Phuong Dinh

  • Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer

    José Baselga;Patricia Gómez;Richard Greil;Sofia Braga

  • Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial

    Sophie Leboulleux;Lars Bastholt;Thomas Michael Krause;Christelle de la Fouchardiere

  • Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial

    G Gebhart;L. E Lamberts;Z Wimana;C Garcia

  • Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

    José Trigo;Vivek Subbiah;Benjamin Besse;Benjamin Besse;Victor Moreno

  • Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial

    Ahmad Awada;Ramon Colomer;Kenichi Inoue;Igor Bondarenko

  • Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine

    Javier Cortes;Linda Vahdat;Joanne L. Blum;Chris Twelves

  • Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer.

    Lillian L. Siu;Ahmad Awada;Chris H. Takimoto;Martine Piccart

  • Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer

    F Rothé;J-F Laes;Diether Lambrechts;Dominiek Smeets

  • Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies

    Chris C. Twelves;Javier Cortes;Linda L.T. Vahdat;Martin M. Olivo

Frequent Co-Authors

Martine Piccart
Martine Piccart Université Libre de Bruxelles
Javier Cortes
Javier Cortes Vall d'Hebron Hospital Universitari
Marianne Paesmans
Marianne Paesmans Université Libre de Bruxelles
Evandro de Azambuja
Evandro de Azambuja Université Libre de Bruxelles
Fatima Cardoso
Fatima Cardoso Champalimaud Foundation
Véronique Diéras
Véronique Diéras Institute Curie
Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Hans Wildiers
Hans Wildiers KU Leuven
Denis Larsimont
Denis Larsimont Université Libre de Bruxelles
Christos Sotiriou
Christos Sotiriou Université Libre de Bruxelles

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying medicine in the USA opens up diverse career pathways beyond traditional medical practice. Many students consider related online degrees that offer flexibility and affordability. For those interested in advanced nursing, exploring the cheapest DNP program options can help you achieve a doctoral-level qualification at a lower cost.

If you're passionate about pharmaceuticals, attending a pharmacy school online provides a convenient way to earn a PharmD degree without relocating. Alternatively, careers in health administration and data management are growing. Getting an online health information management degree prepares you for roles in medical records, analysis, and information systems.

Entry-level options are also available for those seeking faster pathways into healthcare. Completing a low cost medical coding and billing online program can help you quickly start working in healthcare administration. Each pathway offers its own set of rewards and challenges, so it's important to choose a degree that matches your career goals.

Best Scientists Citing Ahmad Awada

Trending Scientists